⚠ For research purposes only — not for human consumption. Not evaluated by the FDA.
CJC-1295/Ipamorelin
5mg/5mg
CJC-1295/Ipamorelin is a growth hormone-releasing (GHR) peptide blend combining a GHRH analogue with a GHRP. Research examines synergistic growth hormone stimulation, body composition effects, and tissue repair pathways. Both compounds act on the ghrelin receptor to drive GH release through distinct mechanisms.
How to Order
Preclinical Research Areas
- ●Growth hormone pathway activation
- ●Body composition and recovery research
- ●Synergistic GHRH/GHRP mechanism
- ●Tissue repair studies
- ●IGF-1 axis investigation
Follow published research literature for study protocols. Combination products require individual compound reference data. Refer to individual COAs for confirmed doses.
⚠ This information is from published scientific literature and is provided strictly for research reference. Not for human use. Follow all applicable laws and institutional protocols.
CJC-12955 is a GHRH (growth hormone-releasing hormone) analogue studied for sustained GH elevation. Ipamorelin is a selective GHRP (growth hormone-releasing peptide) with a strong safety profile in research literature. The combination is well-documented in published studies as a synergistic growth hormone secretagogue blend. Both compounds have independent research bases and are commonly studied together for recovery and body composition endpoints.
📊 Independent verification. Each report below is issued by a third-party analytical laboratory. Results confirm compound identity and purity. Documents are provided for research transparency only.
- Every order includes a Certificate of Analysis (CoA) from a third-party lab
- Ships within 1–2 business days from Wichita, KS
- Domestic US shipping only
- Discreet packaging, no product names on external labels
- Questions? Email optilifewellness@polsia.app
Need reconstitution water?
Bacteriostatic water is required to reconstitute lyophilized peptides for research applications.
